Avid Bioservices (CDMO) Set to Announce Earnings on Monday

Avid Bioservices (NASDAQ:CDMO) is scheduled to announce its earnings results after the market closes on Monday, September 9th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Avid Bioservices has set its FY 2025 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

Avid Bioservices (NASDAQ:CDMO) last announced its quarterly earnings results on Tuesday, July 2nd. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.10). The business had revenue of $42.98 million for the quarter, compared to analysts’ expectations of $42.60 million. Avid Bioservices had a negative return on equity of 11.27% and a negative net margin of 100.57%.

Avid Bioservices Stock Down 1.9 %

Shares of NASDAQ CDMO opened at $8.83 on Friday. The company has a market capitalization of $563.27 million, a price-to-earnings ratio of -4.00 and a beta of 1.37. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.46 and a quick ratio of 0.31. The business has a 50-day moving average of $9.65 and a two-hundred day moving average of $8.26. Avid Bioservices has a 1 year low of $4.07 and a 1 year high of $12.20.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price target on shares of Avid Bioservices in a report on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.67.

Insider Activity at Avid Bioservices

In related news, CEO Nicholas Stewart Green sold 7,657 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $7.54, for a total value of $57,733.78. Following the transaction, the chief executive officer now owns 212,314 shares in the company, valued at approximately $1,600,847.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 9,216 shares of company stock worth $69,984 in the last quarter. Company insiders own 2.39% of the company’s stock.

Avid Bioservices Company Profile

Avid Bioservices, Inc, a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support.